Actuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer

Reuters

Aug 25, 2025

Actuate <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer

Actuate Therapeutics Inc. has announced plans for a Phase 1b clinical trial to evaluate the combination of their drug elra with Incyte Corporation's PD-1 inhibitor retifanlimab and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy for advanced pancreatic adenocarcinoma. This study will be conducted in collaboration with UPMC Hillman Cancer Center and Incyte. The trial aims to explore synergistic opportunities for patients who have not yet received systemic therapy and to assess ways to optimize elraglusib's potential through a complementary multi-agent approach. Results from this trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064578) on August 25, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2562824030"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562824030\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562824030?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562824030","market":"fut","top_or_hot":-1,"title":"Actuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actuate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ACTU\">Actuate Therapeutics Inc</a>. has announced plans for a Phase 1b clinical trial to evaluate the combination of their drug elra with Incyte Corporation's PD-1 inhibitor retifanlimab and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy for advanced pancreatic adenocarcinoma. This study will be conducted in collaboration with UPMC Hillman Cancer Center and Incyte. The trial aims to explore synergistic opportunities for patients who have not yet received systemic therapy and to assess ways to optimize elraglusib's potential through a complementary multi-agent approach. Results from this trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064578) on August 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-25 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actuate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ACTU\">Actuate Therapeutics Inc</a>. has announced plans for a Phase 1b clinical trial to evaluate the combination of their drug elra with Incyte Corporation's PD-1 inhibitor retifanlimab and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy for advanced pancreatic adenocarcinoma. This study will be conducted in collaboration with UPMC Hillman Cancer Center and Incyte. The trial aims to explore synergistic opportunities for patients who have not yet received systemic therapy and to assess ways to optimize elraglusib's potential through a complementary multi-agent approach. Results from this trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064578) on August 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INCY","symbol_name":"因塞特医疗","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nNDL1s25yf:1","article_id":"2562824030","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562824030","pubTimestamp":1756130472,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Actuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer. Actuate Therapeutics Inc. has announced plans for a Phase 1b clinical trial to evaluate the combination of their drug elra with Incyte Corporation's PD-1 inhibitor retifanlimab and modified FOLFIRINOX  as frontline therapy for advanced pancreatic adenocarcinoma. This study will be conducted in collaboration with UPMC Hillman Cancer Center and Incyte. The trial aims to explore synergistic opportunities for patients who have not yet received systemic therapy and to assess ways to optimize elraglusib's potential through a complementary multi-agent approach. Results from this trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INCY":"因塞特医疗","BK4550":"红杉资本持仓","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","ACTU":"Actuate Therapeutics Inc"},"translate_title":"Actuate Therapeutics宣布Elra联合Retifanlimab和mFOLFIRINOX治疗晚期胰腺癌的新1b期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9,"ACTU":0.9},"content_text":"Actuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer\n    \n\nActuate Therapeutics Inc. has announced plans for a Phase 1b clinical trial to evaluate the combination of their drug elra with Incyte Corporation's PD-1 inhibitor retifanlimab and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy for advanced pancreatic adenocarcinoma. This study will be conducted in collaboration with UPMC Hillman Cancer Center and Incyte. The trial aims to explore synergistic opportunities for patients who have not yet received systemic therapy and to assess ways to optimize elraglusib's potential through a complementary multi-agent approach. Results from this trial have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064578) on August 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}